Antisoma value slashed in half after failure of new cancer drug

One of the most advanced drugs to have been developed by a UK biotech has spectacularly failed its clinical trials, sending shares in the company that owns it down 50 per cent and raising questions over the viability of the entire industry.

Antisoma's pill was no more effective against ovarian cancer than a placebo, the company said yesterday, and the product is to be abandoned after 15 years of work costing an estimated £20m. The unequivocal judgement came as a disappointment to those who had hoped a successful outcome would give a boost to investor interest in the fragile biotech sector. It is also a blow to those who bought into a placing and open offer of Antisoma shares at 40p last November. Yesterday, they fell 24.5p to 20p.

More than 420 women in 17 countries took part in the trials and, although the data will be presented at cancer conferences in an attempt to assist understanding of the disease, there is no chance of it being tried in other cancers. Glyn Edwards, the chief executive, said: "It is a definitive result and there is no future for this drug in any of its indications."

The product, codenamed R1549 but previously known as pemtumomab, has had a chequered history. It was originally licensed to Abbott Laboratories, the US pharmaceuticals giant, but Abbott tried to renegotiate terms in 2002 after equivocal data from Phase II trials. It was taken up by Roche when the Swiss giant did its wide-ranging licensing deal with Antisoma in 2002.

Roche said the disappointment would not affect its relationship with Antisoma, which has, in effect, been annexed as a research and development laboratory for the Swiss group. It is funding earlier-stage trials of a breast cancer drug and has options over other products developed by Antisoma. Mr Edwards said Antisoma has more than two years of cash left, and this would most likely be augmented by milestone payments from Roche, but analysts said there was more pressure on him to buy in an extra product to bolster the pipeline of new drug.

The company raised £15.2m last year, which it said at the time would fund the existing pipeline. One investor who bought in at the placing - and sold out yesterday - said he had been buying "an option" on the success of R1549.

The failure of the product prompted handwringing across the UK biotech sector, whose failure to produce blockbuster drugs is often contrasted with the United States. Yesterday, Roche revealed that another of its partners, Genentech of San Francisco, had successfully completed trials of Tarceva for lung cancer.

Rare successes include Humira, a rheumatoid arthritis drug discovered using know-how at Cambridge Antibody Technology, but which is now the subject of a bitter dispute over royalties between CAT and Abbott, which developed it.

David Oxlade, the chief executive of Xenova, whose brain cancer drug Tariquidar was all but abandoned last year, said that the heavy focus investors had been putting on Antisoma's long-awaited trials results highlighted just how thin the UK industry's pipeline is. "The industry is 10-15 years behind the US. It is easier to obtain larger sums of money in the US than in Europe, so their companies have more money to build the depth and breadth of portfolio that allows you to survive the inevitable disappointments."

Andy Smith, the fund manager of the 3i Biosciences investment trust, worries that the biotech sector's modest recent bounce means it is nearer the top of the cycle of investor sentiment than the bottom.

Club legend Paul Scholes is scared United could disappear into 'the wilderness'
A model of a Neanderthal man on display at the National Museum of Prehistory in Dordogne, France
Dawkins: 'There’s a very interesting reason why a prince could not turn into a frog – it's statistically too improbable'
newsThat's Richard Dawkins on babies with Down Syndrome
Malky Mackay salutes the Cardiff fans after the 3-1 defeat at Liverpool on Sunday
footballFormer Cardiff boss accused of sending homophobic, racist and messages
Rodgers showered praise on Balotelli last week, which led to speculation he could sign the AC Milan front man
Life and Style
life – it's not, says Rachel McKinnon
Arts and Entertainment
Eye of the beholder? 'Concrete lasagne' Preston bus station
architectureWhich monstrosities should be nominated for the Dead Prize?
Arts and Entertainment
Arctic Monkeys headline this year's Reading and Leeds festivals, but there's a whole host of other bands to check out too
music(who aren't Arctic Monkeys)
Lizards, such as Iguanas (pictured), have a unique pattern of tissue growth
Anna Nicole Smith died of an accidental overdose in 2007
Life and Style
food + drink
Arts and Entertainment
'The Great British Bake Off' showcases food at its most sumptuous
tvReview: Bread-making skills of the Bake Off hopefuls put to the test
ebooksAn evocation of the conflict through the eyes of those who lived through it
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...

Test Lead (C#, Java, HTML, SQL) Kingston Finance

£40000 - £55000 per annum: Harrington Starr: A Global Financial Service Organi...

Access/Teradata Developer, Banking, Bristol £400pd

£375 - £400 per day: Orgtel: Access / Teradata Developer - Banking - Bristol -...

Quantitative Analyst (Financial Services, Graduate, SQL, VBA)

£45000 per annum: Harrington Starr: Quantitative Analyst (Financial Services, ...

Day In a Page

Middle East crisis: We know all too much about the cruelty of Isis – but all too little about who they are

We know all too much about the cruelty of Isis – but all too little about who they are

Now Obama has seen the next US reporter to be threatened with beheading, will he blink, asks Robert Fisk
Neanderthals lived alongside humans for centuries, latest study shows

Final resting place of our Neanderthal neighbours revealed

Bones dated to 40,000 years ago show species may have died out in Belgium species co-existed
Scottish independence: The new Scots who hold fate of the UK in their hands

The new Scots who hold fate of the UK in their hands

Scotland’s immigrants are as passionate about the future of their adopted nation as anyone else
Britain's ugliest buildings: Which monstrosities should be nominated for the Dead Prize?

Blight club: Britain's ugliest buildings

Following the architect Cameron Sinclair's introduction of the Dead Prize, an award for ugly buildings, John Rentoul reflects on some of the biggest blots on the UK landscape
eBay's enduring appeal: Online auction site is still the UK's most popular e-commerce retailer

eBay's enduring appeal

The online auction site is still the UK's most popular e-commerce site
Culture Minister Ed Vaizey: ‘lack of ethnic minority and black faces on TV is weird’

'Lack of ethnic minority and black faces on TV is weird'

Culture Minister Ed Vaizey calls for immediate action to address the problem
Artist Olafur Eliasson's latest large-scale works are inspired by the paintings of JMW Turner

Magic circles: Artist Olafur Eliasson

Eliasson's works will go alongside a new exhibition of JMW Turner at Tate Britain. He tells Jay Merrick why the paintings of his hero are ripe for reinvention
Josephine Dickinson: 'A cochlear implant helped me to discover a new world of sound'

Josephine Dickinson: 'How I discovered a new world of sound'

After going deaf as a child, musician and poet Josephine Dickinson made do with a hearing aid for five decades. Then she had a cochlear implant - and everything changed
Greggs Google fail: Was the bakery's response to its logo mishap a stroke of marketing genius?

Greggs gives lesson in crisis management

After a mishap with their logo, high street staple Greggs went viral this week. But, as Simon Usborne discovers, their social media response was anything but half baked
Matthew McConaughey has been singing the praises of bumbags (shame he doesn't know how to wear one)

Matthew McConaughey sings the praises of bumbags

Shame he doesn't know how to wear one. Harriet Walker explains the dos and don'ts of fanny packs
7 best quadcopters and drones

Flying fun: 7 best quadcopters and drones

From state of the art devices with stabilised cameras to mini gadgets that can soar around the home, we take some flying objects for a spin
Joey Barton: ‘I’ve been guilty of getting a bit irate’

Joey Barton: ‘I’ve been guilty of getting a bit irate’

The midfielder returned to the Premier League after two years last weekend. The controversial character had much to discuss after his first game back
Andy Murray: I quit while I’m ahead too often

Andy Murray: I quit while I’m ahead too often

British No 1 knows his consistency as well as his fitness needs working on as he prepares for the US Open after a ‘very, very up and down’ year
Ferguson: In the heartlands of America, a descent into madness

A descent into madness in America's heartlands

David Usborne arrived in Ferguson, Missouri to be greeted by a scene more redolent of Gaza and Afghanistan
BBC’s filming of raid at Sir Cliff’s home ‘may be result of corruption’

BBC faces corruption allegation over its Sir Cliff police raid coverage

Reporter’s relationship with police under scrutiny as DG is summoned by MPs to explain extensive live broadcast of swoop on singer’s home